Ligand Pharma (LGND)

Ligand Pharma (LGND) Income Statement


Ligand Pharma Income Statement

Last quarter (Q2 2023), Ligand Pharma's total revenue was $26.37M, a decrease of -54.08% from the same quarter last year. In Q2, Ligand Pharma's net income was $2.29M. See Ligand Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 136.65M$ 104.50M$ 241.54M$ 186.42M$ 120.28M$ 251.45M
Cost of Revenue
$ 41.15M$ 52.83M$ 62.18M$ 30.42M$ 11.35M$ 6.34M
Gross Profit
$ 122.33M$ 143.42M$ 179.37M$ 156.00M$ 108.94M$ 245.12M
Operating Expense
$ 92.88M$ 193.21M$ 75.52M$ 147.27M$ 114.66M$ 81.39M
Operating Income
$ 25.03M$ 3.04M$ 103.85M$ 8.73M$ -5.72M$ 163.73M
Net Non Operating Interest Income Expense
$ 4.27M$ 247.00K$ -18.73M$ -19.34M$ -7.32M$ -34.28M
Other Income Expense
$ -86.26M$ -32.73M$ 12.91M$ 73.00K$ 809.67M$ 43.88M
Pretax Income
$ 115.49M$ 36.01M$ 72.20M$ -10.54M$ 796.64M$ 173.33M
Tax Provision
$ 58.53M$ 41.23M$ -4.15M$ -7.55M$ 167.34M$ 30.01M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ 56.97M$ -5.22M$ 76.35M$ -2.98M$ 629.30M$ 143.32M
Basic EPS
$ 3.55$ -1.98$ 2.15$ -0.18$ 33.13$ 6.77
Diluted EPS
$ 3.43$ -1.98$ 2.06$ -0.18$ 31.85$ 5.96
Basic Average Shares
$ 68.09M$ 16.87M$ 26.66M$ 16.18M$ 19.00M$ 21.16M
Diluted Average Shares
$ 69.70M$ 16.87M$ 27.65M$ 16.18M$ 19.76M$ 24.07M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
$ 1.31--$ 4.55$ 3.09$ 7.15
Rent Expense Supplemental
Total Expenses
$ 134.04M$ 246.03M$ 137.69M$ 177.69M$ 126.00M$ 87.73M
Net Income From Continuing And Discontinued Operation
$ 55.30M$ -33.36M$ 76.35M$ -2.98M$ 629.30M$ 143.32M
Normalized Income
$ 3.46M--$ -3.12M$ -13.64M$ 101.67M
Interest Expense
$ 332.00K--$ 27.42M$ 35.74M$ 48.28M
$ 115.57M$ 37.81M$ 91.82M$ 16.88M$ 832.38M$ 221.61M
$ 145.53M$ 89.93M$ 134.67M$ 44.85M$ 876.12M$ 237.40M
Currency in USD

Ligand Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis